408 related articles for article (PubMed ID: 25330404)
1. Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease.
Gaig C; Vilas D; Infante J; Sierra M; García-Gorostiaga I; Buongiorno M; Ezquerra M; Martí MJ; Valldeoriola F; Aguilar M; Calopa M; Hernandez-Vara J; Tolosa E
PLoS One; 2014; 9(10):e108982. PubMed ID: 25330404
[TBL] [Abstract][Full Text] [Related]
2. Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the
Saunders-Pullman R; Ortega RA; Wang C; Raymond D; Elango S; Leaver K; Urval N; Katsnelson V; Gerber R; Swan M; Shanker V; Alcalay RN; Mirelman A; Brumm MC; Mejia-Santana H; Coffey CS; Marek K; Ozelius LJ; Giladi N; Marder KS; Bressman SB
Neurology; 2022 Aug; 99(8):e814-e823. PubMed ID: 35995594
[TBL] [Abstract][Full Text] [Related]
3. Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers.
Pont-Sunyer C; Iranzo A; Gaig C; Fernández-Arcos A; Vilas D; Valldeoriola F; Compta Y; Fernández-Santiago R; Fernández M; Bayés A; Calopa M; Casquero P; de Fàbregues O; Jaumà S; Puente V; Salamero M; José Martí M; Santamaría J; Tolosa E
PLoS One; 2015; 10(7):e0132368. PubMed ID: 26177462
[TBL] [Abstract][Full Text] [Related]
4. Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data.
Silveira-Moriyama L; Guedes LC; Kingsbury A; Ayling H; Shaw K; Barbosa ER; Bonifati V; Quinn NP; Abou-Sleiman P; Wood NW; Petrie A; Sampaio C; Ferreira JJ; Holton J; Revesz T; Lees AJ
Neurology; 2008 Sep; 71(13):1021-6. PubMed ID: 18809839
[TBL] [Abstract][Full Text] [Related]
5. Olfactory dysfunction in LRRK2 G2019S mutation carriers.
Saunders-Pullman R; Stanley K; Wang C; San Luciano M; Shanker V; Hunt A; Severt L; Raymond D; Ozelius LJ; Lipton RB; Bressman SB
Neurology; 2011 Jul; 77(4):319-24. PubMed ID: 21753159
[TBL] [Abstract][Full Text] [Related]
6. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers.
Marras C; Schüle B; Munhoz RP; Rogaeva E; Langston JW; Kasten M; Meaney C; Klein C; Wadia PM; Lim SY; Chuang RS; Zadikof C; Steeves T; Prakash KM; de Bie RM; Adeli G; Thomsen T; Johansen KK; Teive HA; Asante A; Reginold W; Lang AE
Neurology; 2011 Jul; 77(4):325-33. PubMed ID: 21753163
[TBL] [Abstract][Full Text] [Related]
7. Olfaction in LRRK2 Linked Parkinson's Disease: Is It Different from Idiopathic Parkinson's Disease?
Vilas D; Tolosa E; Quintana M; Pont-Sunyer C; Santos M; Casellas A; Valldeoriola F; Compta Y; Martí MJ; Mullol J
J Parkinsons Dis; 2020; 10(3):951-958. PubMed ID: 32310189
[TBL] [Abstract][Full Text] [Related]
8. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
[TBL] [Abstract][Full Text] [Related]
9. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C
Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080
[TBL] [Abstract][Full Text] [Related]
10. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.
Sierra M; Sánchez-Juan P; Martínez-Rodríguez MI; González-Aramburu I; García-Gorostiaga I; Quirce MR; Palacio E; Carril JM; Berciano J; Combarros O; Infante J
Neurology; 2013 Feb; 80(7):621-6. PubMed ID: 23325906
[TBL] [Abstract][Full Text] [Related]
11. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
Marras C; Alcalay RN; Caspell-Garcia C; Coffey C; Chan P; Duda JE; Facheris MF; Fernández-Santiago R; Ruíz-Martínez J; Mestre T; Saunders-Pullman R; Pont-Sunyer C; Tolosa E; Waro B;
Mov Disord; 2016 Aug; 31(8):1192-202. PubMed ID: 27091104
[TBL] [Abstract][Full Text] [Related]
12. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
Alcalay RN; Mirelman A; Saunders-Pullman R; Tang MX; Mejia Santana H; Raymond D; Roos E; Orbe-Reilly M; Gurevich T; Bar Shira A; Gana Weisz M; Yasinovsky K; Zalis M; Thaler A; Deik A; Barrett MJ; Cabassa J; Groves M; Hunt AL; Lubarr N; San Luciano M; Miravite J; Palmese C; Sachdev R; Sarva H; Severt L; Shanker V; Swan MC; Soto-Valencia J; Johannes B; Ortega R; Fahn S; Cote L; Waters C; Mazzoni P; Ford B; Louis E; Levy O; Rosado L; Ruiz D; Dorovski T; Pauciulo M; Nichols W; Orr-Urtreger A; Ozelius L; Clark L; Giladi N; Bressman S; Marder KS
Mov Disord; 2013 Dec; 28(14):1966-71. PubMed ID: 24243757
[TBL] [Abstract][Full Text] [Related]
13. The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.
Sweet ES; Saunier-Rebori B; Yue Z; Blitzer RD
J Neurosci; 2015 Aug; 35(32):11190-5. PubMed ID: 26269629
[TBL] [Abstract][Full Text] [Related]
14. 123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations.
Valldeoriola F; Gaig C; Muxí A; Navales I; Paredes P; Lomeña F; De la Cerda A; Buongiorno M; Ezquerra M; Santacruz P; Martí MJ; Tolosa E
J Neurol; 2011 Jun; 258(6):1126-32. PubMed ID: 21221623
[TBL] [Abstract][Full Text] [Related]
15. The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
Pont-Sunyer C; Tolosa E; Caspell-Garcia C; Coffey C; Alcalay RN; Chan P; Duda JE; Facheris M; Fernández-Santiago R; Marek K; Lomeña F; Marras C; Mondragon E; Saunders-Pullman R; Waro B;
Mov Disord; 2017 May; 32(5):726-738. PubMed ID: 28370517
[TBL] [Abstract][Full Text] [Related]
16. Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene.
Mirelman A; Alcalay RN; Saunders-Pullman R; Yasinovsky K; Thaler A; Gurevich T; Mejia-Santana H; Raymond D; Gana-Weisz M; Bar-Shira A; Ozelius L; Clark L; Orr-Urtreger A; Bressman S; Marder K; Giladi N;
Mov Disord; 2015 Jun; 30(7):981-6. PubMed ID: 25809001
[TBL] [Abstract][Full Text] [Related]
17. The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study).
Pont-Sunyer C; Hotter A; Gaig C; Seppi K; Compta Y; Katzenschlager R; Mas N; Hofeneder D; Brücke T; Bayés A; Wenzel K; Infante J; Zach H; Pirker W; Posada IJ; Álvarez R; Ispierto L; De Fàbregues O; Callén A; Palasí A; Aguilar M; Martí MJ; Valldeoriola F; Salamero M; Poewe W; Tolosa E
Mov Disord; 2015 Feb; 30(2):229-37. PubMed ID: 25449044
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2.
Ruiz-Martínez J; de la Riva P; Rodríguez-Oroz MC; Mondragón Rezola E; Bergareche A; Gorostidi A; Gago B; Estanga A; Larrañaga N; Sarasqueta C; López de Munain A; Martí Massó JF
Mov Disord; 2014 May; 29(6):750-5. PubMed ID: 24357540
[TBL] [Abstract][Full Text] [Related]
19. Olfactory dysfunction in sporadic Parkinson's Disease and LRRK2 carriers.
Johansen KK; Warø BJ; Aasly JO
Acta Neurol Scand; 2014 May; 129(5):300-6. PubMed ID: 23937295
[TBL] [Abstract][Full Text] [Related]
20. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.
Ruiz-Martínez J; Gorostidi A; Goyenechea E; Alzualde A; Poza JJ; Rodríguez F; Bergareche A; Moreno F; López de Munain A; Martí Massó JF
Mov Disord; 2011 Sep; 26(11):2026-31. PubMed ID: 21611983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
